Abstract: A method of forming an acid-doped polyaniline (emeraldine salt) (PANi-ES) solution including steps of: (i) mixing polyaniline (emeraldine base) (PANi-EB) with a PANi-EB solvent and a gel-inhibitor to form a gel-inhibited PANi-EB solution; (ii) removing the gel-inhibitor from the gel-inhibited PANi-EB solution to form a PANi-EB solution; and (iii) adding an acid dopant to the PANi-EB solution to form a PANi-ES solution.

Abstract: A method of forming an acid-doped polyaniline (emeraldine salt) (PANi-ES) solution including steps of: (i) mixing polyaniline (emeraldine base) (PANi-EB) with a PANi-EB solvent and a gel-inhibitor to form a gel-inhibited PANi-EB solution; (ii) removing the gel-inhibitor from the gel-inhibited PANi-EB solution to form a PANi-EB solution; and (iii) adding an acid dopant to the PANi-EB solution to form a PANi-ES solution.

Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

Abstract: The invention disclosed herein is directed to compounds of Formula I [Formula should be entered here] and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma, and other cancers. The invention also includes pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma and other cancers.

Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

Abstract: The invention disclosed herein is directed to compounds of Formula I [Formula should be entered here] and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma, and other cancers. The invention also includes pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma and other cancers.

Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

Abstract: The invention disclosed herein is directed to compounds of Formula I [Formula should be entered here] and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma, and other cancers. The invention also includes pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma and other cancers.

Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

Abstract: A purchasing entity directs the sourcing of one or more parts in a microprocessor-based method. The microprocessor-based method comprises obtaining over a computer network sourcing information from a primary supplier which identifies one or more third party secondary suppliers for one or more parts in a group of parts, ordering the group of parts from the primary supplier, and then issuing a release to the secondary supplier to ship the part to a predetermined location. A computer system for purchasing parts from a secondary supplier that executes the method is also provided.

Abstract: A purchasing entity directs the sourcing of one or more components of a part in a microprocessor-based method. The microprocessor-based method comprises generating a listing for a part that identifies the one or more components. Such a listing is stored in digital electronic form and is accessible by a microcomputer-based system. The purchasing entity then enters into a purchase agreement with a secondary supplier for at least one component of the one or more components. The purchasing entity then obtains a quotation from a primary supplier for the part with the secondary supplier specified as a supplier for at least one component. A computer system for directed sourcing that includes a computer network including one or more computers and which executes the method of the invention is also provided.

Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

Abstract: A purchasing entity directs the sourcing of one or more components of a part in a microprocessor-based method. The microprocessor-based method comprises generating a listing for a part that identifies the one or more components. Such a listing is stored in digital electronic form and is accessible by a microcomputer-based system. The purchasing entity then enters into a purchase agreement with a secondary supplier for at least one component of the one or more components. The purchasing entity then obtains a quotation from a primary supplier for the part with the secondary supplier specified as a supplier for at least one component. A computer system for directed sourcing that includes a computer network including one or more computers and which executes the method of the invention is also provided.

Abstract: A purchasing entity directs the sourcing of one or more parts in a microprocessor-based method. The microprocessor-based method comprises obtaining over a computer network sourcing information from a primary supplier which identifies one or more third party secondary suppliers for one or more parts in a group of parts, ordering the group of parts from the primary supplier, and then issuing a release to the secondary supplier to ship the part to a predetermined location. A computer system for purchasing parts from a secondary supplier that executes the method is also provided.